DArecca James has filed 15 insider transactions across 2 companies since August 2023.
Most recent transaction: a grant/award of 2094 shares of Prestige Consumer Healthcare Inc. ($PBH) on August 05, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 5, 2025 | Prestige Consumer Healthcare Inc. | $PBH | DArecca James | Director | A | Common Stock, par value $0.01 per share | 2094 | $0.00 | 6,591.0000 | 56,171,000 | 46.56% | 0.00% |
| May 30, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | A | Common Stock | 12221 | $0.00 | 34,156.0000 | 50,730,000 | 55.71% | 0.02% |
| May 30, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 5864 | $69.38 | 28,292.0000 | 50,730,000 | 17.17% | 0.01% |
| May 16, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | A | Common Stock | 7111 | $0.00 | 21,935.0000 | 50,730,000 | 47.97% | 0.01% |
| May 16, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | A | Non-qualified Stock Option (Right to Buy) | 15396 | $0.00 | 15,396.0000 | 50,730,000 | 9999.99% | 0.03% |
| May 15, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 622 | $69.38 | 16,070.0000 | 50,730,000 | 3.73% | 0.00% |
| May 16, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 1246 | $70.31 | 14,824.0000 | 50,730,000 | 7.75% | 0.00% |
| May 2, 2025 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 654 | $63.85 | 16,692.0000 | 50,730,000 | 3.77% | 0.00% |
| Aug. 6, 2024 | Prestige Consumer Healthcare Inc. | $PBH | DArecca James | Director | A | Common Stock, par value $0.01 per share | 2202 | $0.00 | 4,497.0000 | 55,717,000 | 95.95% | 0.00% |
| May 17, 2024 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | A | Common Stock | 4439 | $0.00 | 17,346.0000 | 51,397,000 | 34.39% | 0.01% |
| May 17, 2024 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | A | Non-qualified Stock Option (Right to Buy) | 9756 | $0.00 | 9,756.0000 | 51,397,000 | 9999.99% | 0.02% |
| May 16, 2024 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 351 | $94.80 | 12,907.0000 | 51,397,000 | 2.65% | 0.00% |
| May 15, 2024 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 412 | $96.49 | 13,258.0000 | 51,397,000 | 3.01% | 0.00% |
| May 2, 2024 | HAEMONETICS CORP | $HAE | DArecca James | EVP, Chief Financial Officer | F | Common Stock | 432 | $93.33 | 13,670.0000 | 51,397,000 | 3.06% | 0.00% |
| Aug. 1, 2023 | Prestige Consumer Healthcare Inc. | $PBH | DArecca James | Director | A | Common Stock, par value $0.01 per share | 2295 | $0.00 | 2,295.0000 | 54,857,000 | 9999.99% | 0.00% |